Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
BCLI 
Brainstorm Cell Therapeutics Inc (BCLI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: BCLI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $20.68
1 Year Target Price $20.68
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -0.58% | Avg. Invested days 48 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 7.32M USD | Price to earnings Ratio - | 1Y Target Price 20.68 |
Price to earnings Ratio - | 1Y Target Price 20.68 | ||
Volume (30-day avg) 1 | Beta 0.14 | 52 Weeks Range 0.52 - 4.54 | Updated Date 09/14/2025 |
52 Weeks Range 0.52 - 4.54 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.73 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -180.31% | Return on Equity (TTM) -1121.9% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 7061101 | Price to Sales(TTM) - |
Enterprise Value 7061101 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.7 | Shares Outstanding 10376100 | Shares Floating 9405216 |
Shares Outstanding 10376100 | Shares Floating 9405216 | ||
Percent Insiders 11.92 | Percent Institutions 3.79 |
Upturn AI SWOT
Brainstorm Cell Therapeutics Inc
Company Overview
History and Background
Brainstorm Cell Therapeutics Inc. was founded in 2003. The company focuses on developing autologous cell therapies for neurodegenerative diseases. A key milestone was the development and clinical trials of NurOwnu00ae.
Core Business Areas
- NurOwnu00ae Development: The company's primary focus is the development and commercialization of NurOwnu00ae, an autologous MSC-NTF cell therapy for neurodegenerative diseases, particularly Amyotrophic Lateral Sclerosis (ALS).
Leadership and Structure
Chaim Lebovits serves as the Chief Executive Officer. The company has a board of directors and operates with a research and development team focused on clinical trials and regulatory approvals.
Top Products and Market Share
Key Offerings
- NurOwnu00ae: NurOwnu00ae is Brainstorm's lead product, an autologous cell therapy for ALS. Market share data is not readily available, as it has yet to be fully approved by the FDA. Competitors include companies developing ALS treatments such as Biogen (TOFRSENA), Amylyx Pharmaceuticals (RELYVRIO).
Market Dynamics
Industry Overview
The industry involves cell therapy development for neurological disorders, characterized by high unmet needs and regulatory hurdles.
Positioning
Brainstorm is positioned as an innovator in autologous cell therapy for neurodegenerative diseases, focusing primarily on ALS. Its competitive advantage lies in its NurOwnu00ae technology.
Total Addressable Market (TAM)
The global ALS treatment market is expected to reach billions of dollars. Brainstorm is positioning itself to capture a significant share upon regulatory approval of NurOwnu00ae.
Upturn SWOT Analysis
Strengths
- Proprietary NurOwnu00ae technology
- Focus on addressing unmet needs in ALS treatment
- Experienced research and development team
Weaknesses
- Reliance on single product (NurOwnu00ae)
- High cash burn rate
- Uncertainty regarding regulatory approval
Opportunities
- Potential FDA approval of NurOwnu00ae
- Expansion to other neurodegenerative diseases
- Partnerships with larger pharmaceutical companies
Threats
- Regulatory setbacks
- Competition from other ALS treatments
- Financial constraints
Competitors and Market Share
Key Competitors
- BIIB
- AMLY
- ITCI
Competitive Landscape
Brainstorm faces intense competition in the ALS treatment market. Competitors have approved treatments, creating a challenging environment.
Growth Trajectory and Initiatives
Historical Growth: Growth is primarily based on clinical trial advancements rather than revenue generation.
Future Projections: Future growth depends heavily on FDA approval of NurOwnu00ae and subsequent commercialization.
Recent Initiatives: Recent initiatives include completing Phase 3 clinical trials and engaging with regulatory agencies.
Summary
Brainstorm Cell Therapeutics is a high-risk, high-reward company focused on cell therapy for ALS. The company's future hinges on NurOwnu00ae approval. Successful regulatory approval could transform the company; failure would significantly impact its viability. Key factors to watch are clinical trial results and regulatory decisions.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company reports
- SEC filings
- Market research reports
- Analyst estimates
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market data can change, and readers should conduct their own research.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Brainstorm Cell Therapeutics Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2003-08-28 | President & CEO Mr. Chaim Lebovits | ||
Sector Healthcare | Industry Biotechnology | Full time employees 29 | Website https://www.brainstorm-cell.com |
Full time employees 29 | Website https://www.brainstorm-cell.com | ||
Brainstorm Cell Therapeutics Inc. a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is involved in the development of NurOwn, which has completed Phase IIIb clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for treatment of other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.